JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on SpringWorks Therapeutics (NASDAQ:SWTX) and raises the price target from $73 to $74.
March 06, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on SpringWorks Therapeutics and raises the price target from $73 to $74.
The increase in price target by a reputable analyst like Anupam Rama from JP Morgan is a positive signal for investors, indicating a bullish outlook on the stock. This adjustment suggests that the analyst sees potential for higher future performance or valuation of SpringWorks Therapeutics, which could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100